Nausea deferoxamine

Nausea and vomiting often develop in patients with rheumatoid arthritis after 4—12 days of treatment with deferoxamine, presumably as a result of chelation of iron from the central nervous system (37). Two patients who took the phenothiazine derivative prochlorperazine during treatment of rheumatoid arthritis with deferoxamine lost consciousness for 48-72 hours, possibly because this combination of drugs removed essential iron from the nervous system (38). 

Gastrointestinal upsets are frequent after parenteral administration of deferoxamine (12). In addition to nausea, vomiting, and abdominal cramps, passage of black stools can occur, perhaps because of increased stool iron content. Nausea, anorexia, and vomiting often occur when deferoxamine is used in rheumatoid arthritis or Alzheimer s disease (32,83). 

Nineteen patients experienced adverse events in the deferoxamine cohort of a prospective, randomised, phase II study comparing deferoxamine with deferasirox in sickle cell disease patients (n=68) [50 ]. The side effects were diarrhoea, nausea, abdominal pain, injection site irritation and injection site pain (all with an incidence of 3.6%). 

A controlled clinical trial on 26 patients with beta-tiialassaemia major compared combination therapy (deferiprone (n=12, 75 mg/kg/day three times per day) and deferoxamine (30-50mg/kg subcutaneously every other day)) with control monotherapy (deferoxamine (n = 14, 30-50 mg/kg/day subcufaneously for 6-12h/day, 5-6 day per week)) [56 ]. Side effects of combined fherapy included nausea (8.3%) and arfhropathy (8.3%), with a transient neutropenia... 

---